The objective of this real-world study was to assess associations between current use of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of MACCE and HF in adults with T2D and without known CVD. This is important because previous studies have largely focussed on the benefits of these medicines in “high-risk” patients and have not been designed to detect primary prevention benefits. Interestingly, the investigators also assessed the potential benefits of using SGLT-2 inhibitors and GLP-1 receptor agonists in combination. This review is sponsored by Boehringer Ingelheim and Eli Lilly.
The full text of the study is available here: Wright, A.K. et al. Diabetes Care 2022; 45(4):909-918 Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes.
Please login below to download this issue (PDF)